This 3-page resource is a conversation guide for healthcare providers about how to talk to patients about latent TB infection.
This 2-page resource is a conversation guide for patients about how to talk to healthcare providers about TB risk, understand the testing process, and discuss treatment options.
The fact sheet provides information on myths and facts about inactive TB.
This fact sheet provides a detailed overview of the risk factors, testing process, and treatment options for inactive TB.
A one-page visual overview of the testing and treatment of inactive TB that can be used as a poster.
A one-page visual overview of the testing and treatment of inactive TB that can be used as a poster.
This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.
This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.
This material was developed for clinicians to use with patients that are prescribed the 12-dose regimen for the treatment of latent TB infection. There is space to write treatment schedules, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 12-dose regimen.
The patient education brochure was developed for clinicians to use with patients while discussing the 12-dose regimen for the treatment of latent TB infection. The brochure contains information on latent TB infection, the 12-dose regimen, and adverse events.
